Ambrisentan

BNF:

2.5.1

Status:

Red

Decision Date:

None

Comments

Treatment of pulmonary arterial hypertension in adults, adolescents and children (aged ≥8 to <18 years) of WHO Functional Class II to III, including use in combination treatment [new 2.5mg tablet formulation].

NHS England commissioned.  To be used in line with NHSE commissioning intentions.

Red Drug Classifications

• 1: Requiring specialist assessment to enable patient selection, initiation and ongoing treating
• 2: Requiring long term on-going monitoring of efficacy by a specialist and not suitable for shared care
• 3: Requiring long term on-going monitoring of toxicity by a specialist (either because of difficulty in recognising side effects or high cost of investigations to identify toxicity)

search again